Internal Medicine, Endocrinology, Diabetes, & Metabolism · Fayetteville, NC
NPI
1497045496
Since 2011
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
101 Robeson St, Suite 405
Fayetteville, NC, 28301
Phone (910) 615-1623
Groups this clinician bills Medicare through
Medicare paid, 2024
$58K
1,098 services
Medicare patients, 2024
389
Average age 70
Drug cost, 2024
$5.9M
9,510 prescriptions
Company payments, 2025
$41.67
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nduche C Onyeaso was code 99214 (office e&m - established), 689 times for 325 patients. In total Nduche C Onyeaso billed 1,098 services in 10 codes, and Medicare paid $58K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 689 | 325 | $64.94 | $45K |
| 95251 Test - Miscellaneous | Office | 233 | 105 | $23.66 | $5,514 |
| 99213 Office E&M - Established | Office | 72 | 66 | $42.90 | $3,089 |
| 99204 Office E&M - New | Office | 48 | 48 | $83.19 | $3,993 |
| 99211 Office E&M - Established | Office | 19 | 19 | $4.89 | $92.85 |
By year: 2022 $79K for 1,367 services; 2023 $66K for 1,185 services; 2024 $58K for 1,098 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 16 | 11 | $3.39 | $54.25 |
Medicare prescription drug claims, 2024
In 2024, the drug Nduche C Onyeaso prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,074 prescriptions and refills. In total Nduche C Onyeaso wrote 9,510 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,074 | 1,711 | 234 | $1.6M |
| Trulicity Dulaglutide | 745 | 1,121 | 173 | $1.1M |
| Jardiance Empagliflozin | 560 | 1,153 | 150 | $683K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 510 | 1,270 | 187 | $69K |
| Metformin Hcl Er Metformin Hcl | 466 | 1,032 | 129 | $4,207 |
| Metformin Hcl Generic | 461 | 1,034 | 124 | $2,856 |
| Levothyroxine Sodium Generic | 430 | 947 | 108 | $4,024 |
| Atorvastatin Calcium Generic | 352 | 797 | 110 | $2,699 |
| Mounjaro Tirzepatide | 268 | 426 | 65 | $460K |
| Glimepiride Generic | 175 | 423 | 53 | $1,180 |
| Tresiba Flextouch U-100 Insulin Degludec | 175 | 359 | 48 | $121K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 167 | 319 | 39 | $185K |
| Humalog Kwikpen U-100 Insulin Lispro | 162 | 375 | 63 | $45K |
| Farxiga Dapagliflozin Propanediol | 157 | 280 | 43 | $154K |
| Novolog Flexpen Insulin Aspart | 148 | 246 | 55 | $27K |
Brand drugs: 6,059 claims; generic drugs: 2,550 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nduche C Onyeaso $41.67 ($41.67 in general payments such as food, travel and fees) from 2 companies. The largest payer was Neurocrine BioSciences, Inc. with $24.04.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.